دورية أكاديمية
Serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab
| العنوان: | Serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab |
|---|---|
| المؤلفون: | Bertani L., Fornai M., Fornili M., Antonioli L., Benvenuti L., Tapete G., Baiano Svizzero G., Ceccarelli L., Mumolo M. G., Baglietto L., de Bortoli N., Bellini M., Marchi S., Costa F., Blandizzi C. |
| المساهمون: | Bertani, L., Fornai, M., Fornili, M., Antonioli, L., Benvenuti, L., Tapete, G., Baiano Svizzero, G., Ceccarelli, L., Mumolo, M. G., Baglietto, L., de Bortoli, N., Bellini, M., Marchi, S., Costa, F., Blandizzi, C. |
| سنة النشر: | 2020 |
| المجموعة: | ARPI - Archivio della Ricerca dell'Università di Pisa |
| الوصف: | Background: Oncostatin M is upregulated in Crohn's disease inflamed intestinal mucosa, and has been suggested as a promising biomarker to predict responsiveness to anti-TNF therapy in patients with inflammatory bowel diseases. Aim: To evaluate the suitability of serum oncostatin M as a predictive marker of response to infliximab in Crohn's disease. Methods: We included patients treated with infliximab monotherapy. All patients underwent colonoscopy at week 54 to evaluate mucosal healing. Serum oncostatin M and faecal calprotectin were measured at baseline and after 14weeks of treatment. Mann-Whitney test was used to evaluate correlation of oncostatin M and faecal calprotectin at baseline and week 14 with mucosal healing at week 54. Their accuracy in predicting mucosal healing was assessed by area under the curve (AUC). Results: In a cohort of 45 included patients, 27 displayed mucosal healing. At both baseline and week 14, oncostatin M levels were significantly lower in patients with mucosal healing than in patients not achieving this endpoint (P<0.001). Faecal calprotectin levels at week 14 were lower also in responders than nonresponders (P<0.001). Oncostatin M values at baseline and week 14 were significantly associated (Spearman correlation=0.92, P<0.001). The diagnostic accuracy of oncostatin M at baseline in predicting mucosal healing (AUC=0.91) was greater than faecal calprotectin (AUC=0.51, P<0.001). Conclusion: These results suggest that oncostatin M can predict the outcome of infliximab treatment. Compared with faecal calprotectin, the predictive capability of oncostatin M was appreciable at baseline, thus indicating oncostatin M as a promising biomarker for driving therapeutic choices in Crohn's disease. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | ELETTRONICO |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/32506635; info:eu-repo/semantics/altIdentifier/wos/WOS:000538296000001; volume:52; issue:2; firstpage:284; lastpage:291; numberofpages:8; journal:ALIMENTARY PHARMACOLOGY & THERAPEUTICS; https://hdl.handle.net/11568/1045324Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85085983159 |
| DOI: | 10.1111/apt.15870 |
| الإتاحة: | https://doi.org/10.1111/apt.15870Test https://hdl.handle.net/11568/1045324Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.CA1578B8 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1111/apt.15870 |
|---|